Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04375150 · ClinicalTrials.gov registry record
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 355
- Enrollment target
NCT04375150: Completed study, sponsored by Pfizer.
NCT04375150 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 355 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04375150 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
Primary Outcome
Number of participants with first line treatment regimen prescribed following a primary and secondary diagnosis of advanced/metastatic disease is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Interventions
- DRUG Tyrosine kinase inhibitor (TKI)
- DRUG Immuno-oncology (IO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2022-10-28 |
What the finished NCT04375150 record still lists
NCT04375150 is an observational study that tracks outcomes without assigning an intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Tyrosine kinase inhibitor (TKI) is the first listed.
NCT04375150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04375150 about?
NCT04375150 is a clinical study titled "Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC". The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
What is the current status of trial NCT04375150?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2019-12-02. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT04375150?
The interventions under investigation include: Tyrosine kinase inhibitor (TKI) (DRUG), Immuno-oncology (IO) (DRUG).
Who is sponsoring clinical trial NCT04375150?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI